ZhuNZhangDWangW, et al.A novel coronavirus from patients with pneumonia in China, 2019. N Eng J Med2020; 382: 727–733.
2.
HammingITimensWBluthuisMLC, et al.Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol2004; 203: 631–637.
3.
ChenYGuoYPanY, et al.Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun2020; 525: 135–140.
4.
MiesbachWMakrisM. COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost2020; 26: 1–7.
5.
HenryBMVikseJBenoitS, et al.Hyperinflammation and derangement of renin–angiotensin–aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta2020; 507: 167–173.
6.
ChenNZhouMDangX, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet2020; 395: 507–513.
7.
AksuKDonmezAGokhanK, et al.Inflammation-induced thrombosis: Mechanisms, disease associations and management. Curr Pharm Des2012; 18: 1478–1493.
8.
ZhangLFengXZhangD, et al.Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China (prevalence, risk factors, and outcome). Circulation2020; 142: 114–128.
9.
KlokFAKruipMJHAvan der MeerNJM, et al.Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res2020; 191: 145–147.
10.
RaliPO’CorragainOOresanyaL, et al.Incidence of venous thromboembolism in coronavirus disease 2019: An experience from a single large academic center. J Vasc Surg Venous Lymphat Disord2021; 9: 585–591.
11.
MiddeldorpSCoppensMvan HaapsT, et al.Incidence of venous thromboembolism in hospitalized patients with COVID-19. Thromb Haemost2020; 18: 1995–2002.
12.
PiazzaGCampiaUHurwitzS, et al.Registry of arterial and venous thromboembolic complications in patients with COVID-19. JACC2020; 76: 2060–2072.
13.
WuCChenXCaiY, et al.Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med2020; 180: 934–943.
14.
WangDHuBHuC, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA2020; 323: 1061–1069.
15.
CuiSChenSLiX, et al.Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemos2020; 18: 1421–1424.
16.
HelmsJTacquardCSeveracF, et al.High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med2020; 46: 1089–1098.
17.
GilMBarouqaMSzymanskiJ, et al.Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open2020; 3: 1–4.
18.
GuanWHuYLiangW, et al.Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med2020; 382: 1708–1720.
19.
GrimnesGHorveiLTichelaarV, et al.: Neutrophil to lymphocyte ratio and future risk of venous thromboembolism and mortality: The Tromsø study. Haematologica2016; 101:e401.
20.
GoshuaGPineAMeizlishM, et al.Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol2020; 7: e575–e582.
21.
HeitJO’FallonWPettersonT, et al.Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med2002; 162: 1245–1248.
22.
FauvelCWeizmanOTrimailleA, et al.Pulmonary embolism in COVID-19 patients: A French multicentre cohort study. Eur Heart J2020; 41: 3058–3068.
23.
GoldhaberSGrodsteinFStampferM, et al.A prospective study of risk factors for pulmonary embolism in women. JAMA1997; 277: 642–645.
24.
MroavicBHipszerBEpsteinR, et al.Metabolic syndrome increases risk for pulmonary embolism after hip and knee arthroplasty. Croat Med J2013; 54: 355–361.
25.
WatchmakerJGoldmanDLeeJ, et al.Increased incidence of acute pulmonary embolism in emergency department patients during the COVID-19 pandemic. Acad Emerg Med2020; 27: 1340–1343.
26.
PoissyJGoutayJCaplanM, et al.Pulmonary embolism in patients with COVID-19. Circulation2020; 142: 184–186.
27.
FrantzeskakiFArmaganidisAOrfanosS. Immunothrombosis in acute respiratory distress syndrome: Cross talks between inflammation and coagulation. Respiration2017; 93: 212–225.
28.
TaylorFTohCHootsW, et al.Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost2001; 86: 1327–1330.
29.
TangNLiDWangX, et al.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost2020; 18: 844–847.
30.
TzotzosSFischerBFischerH, et al.Incidence of ARDS and outcomes in hospitalized patients with COVID-19: A global literature survey. Crit Care2020; 24:516.
31.
ThachilJTangNGandoS, et al.ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost2020; 18: 1023–1026.
32.
ChoEMcClellandPChengO, et al.Utility of D-dimer for diagnosis of deep vein thrombosis in coronavirus disease-19 infection. J Vasc Surg Venous Lymphat Disord2021; 9: 47–53.
33.
Leonard-LorantIDelabrancheXSeveracF, et al.Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-dimer levels. Radiology2020; 296: E189–E191.
34.
MouhatBBesuttiMBouillerK, et al.Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J2020; 56: 2001811.
35.
ZhangYZhangZWeiR, et al.IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p. Arterioscler Thromb Vasc Biol2020; 40: 323–334.
36.
EspallargasISevillaJChiadradiaD, et al.CT imaging of pulmonary embolism in patients with COVID-19 pneumonia: A retrospective analysis. Eur Radiol2021; 31: 1915–1922.
37.
DujardinRHilderinkBHaksteenW, et al.Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. Thromb Res2020; 196: 308–312.
38.
MooresLTritschlerTBrosnahanS, et al.Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: Chest guideline and expert panel report. Chest2020; 158: 1143–1163.
39.
ConnorsJLevyJH. COVID-19 and its implications for thrombosis and anticoagulation. Blood2020; 135: 2033–2040.
40.
BikdeliBMadhavanMJimenezD, et al.COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. JACC2020; 75: 2950–2973.
41.
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health, www.covid19treatmentguidelines.nih.gov/(2020, accessed 20 October 2020).
42.
BilalogluSAphinyanaphongsYJonesS, et al.Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA2020; 324: 800–801.
43.
GuoTFanYChenM, et al.Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). AMA Cardiol2020; 5: 811–818.
44.
ShiSQinMShenB, et al.Association of cardiac injury With mortality in hospitalized patients With COVID-19 in Wuhan, China. JAMA Cardiol2020; 5: 802–810.
45.
SiripanthongBNazarianSMuserD, et al.Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm2020; 17: 1463–1471.
46.
GarberichRJafferFDixonS, et al.Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. JACC2020; 75: 2871–2878.
47.
XiangDXiangXZhangW, et al.Management and outcomes of patients with STEMI during the COVID-19 pandemic in China. JACC2020; 76: 1318–1324.
48.
BaldiESechiGPrimiR, et al.Out-of-hospital cardiac arrest during the COVID-19 outbreak in Italy. N Engl J Med2020; 383: 496–498.
49.
LiuYMuSLiX, et al.Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res2019; 238: 175–185.
50.
MummeryRRiderC. Characterization of the heparin-binding properties of IL-6. J Immunol2000; 165: 5671–5679.
51.
EndresPRosovskyRZhaoS, et al.Filter clotting with continuous renal replacement therapy in COVID-19. J Thromb Thrombolysis2020; 51: 966–970.
52.
LaraRWhyteMGeorgiouL, et al.Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood2020; 136: 1347–1350.
53.
CohenATSpiroTEBüllerHR, et al.Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med2013; 368: 513–523.
54.
WangJHajizadehNMooreE, et al.Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost2020; 00: 1–4.
55.
RichardsonSHirschJNarasimhanM, et al.Presenting characteristics, comorbidities, and outcomes Among 5700 patients hospitalized With COVID-19 in the New York City area. JAMA2020; 323: 2052–2059.
56.
SongJWangGZhangW, et al.Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res2020; 7: E1–E10.
